参考文献/References:
[1] Cavalcante P,Galbardi B,Franzi S,et al.Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epstein-Barr virus infection[J].Immunobiology,2016,221(4):516-527.
[2] Marino M,Scuderi F,Samengo D,et al.Flow cytofluorimetric analysis of Anti-LRP4(LDL Receptor-Related protein 4)autoantibodies in Italian patients with myasthenia gravis[J].PLoS One,2015,10(8):e0135378.
[3] Shen C,Lu Y,Zhang B,et al.Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis[J].J Clin Invest,2013,123(12):5190-5202.
[4] Aricha R,Feferman T,Berrih-Aknin S,et al.Experimental myasthenia gravis in Aire-deficient mice: a Link between Aire and regulatory T cells[J].Ann N Y Acad Sci,2012,1275:107-113.
[5] Kanai T,Uzawa A,Kawaguchi N,et al.HLA-DRB1*14 and DQB1*05 are associated with Japanese anti-MuSK antibody-positive myasthenia gravis patients[J].J Neurol Sci,2016,363:116-118.
[6] Alahgholi-Hajibehzad M,Yilmaz V,Gülsen-Parman Y,et al.Association of HLA-DRB1*14, -DRB1*16 and-DQB1*05 with MuSK-myasthenia gravis in patients from Turkey[J].Hum Immunol,2013,74(12):1633-1635.
[7] Deitiker PR,Oshima M,Smith RG,et al.Association with HLA DQ of early onset myasthenia gravis in Southeast Texas region of the United States[J].Int J Immunogenet,2011,38(1):55-62.
[8] Provenzano C,Ricciardi R,Scuderi F,et al.PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data[J].Neuromuscul Disord,2012,22(2):131-138.
[9] Kakalacheva K,Maurer M,Tackenberg B,et al.Intrathymic Epstein-Barr virus infection is not a prominent feature of myasthenia gravis[J].Ann Neurol,2011,70(3):508-514.
[10] Meyer M,H ls AK,Liersch B,et al.Lack of evidence for Epstein-Barr virus infection in myasthenia gravis thymus[J].Ann Neurol,2011,70(3):515-518.
[11] Serafini B,Cavalcante P,Bernasconi P,et al.Epstein-Barr virus in myasthenia gravis thymus: a matter of debate[J].Ann Neurol,2011,70(3):519.
[12] Cavalcante P,Barberis M,Cannone M,et al.Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis[J].Neurology,2010,74(14):1118-1126.
[13] Jing F,Wei D,Wang D,et al.Lack of Epstein-Barr virus infection in Chinese myasthenia gravis patients[J].Acta Neurol Scand,2013,128(5):345-350.
[14] Ragunathan K,Pathak B,Dahal K.MuSK myasthenia gravis as a manifestation of immune restoration disease in an HIV-positive patient[J].J Neurol,2015,262(3):777-778.
[15] Ghazanfari N,Linsao EL,Trajanovska S,et al.Forced expression of muscle specific kinase slows postsynaptic acetylcholine receptor loss in a mouse model of MuSK myasthenia gravis[J].Physiol Rep,2015,3(12):1-15.
[16] Mori S,Kubo S,Akiyoshi T,et al.Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis[J].Am J Pathol,2012,180(2):798-810.
[17] Zhang B,Tzartos JS,Belimezi M,et al.Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis[J].Arch Neurol,2012,69(4):445-451.
[18] Pevzner A,Schoser B,Peters K,et al.Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis[J].J Neurol,2012,259(3):427-435.
[19] Oshima M,Deitiker PR,Smith RG,et al.T-cell recognition of acetylcholine receptor provides a reliable means for monitoring autoimmunity to acetylcholine receptor in antibody-negative myasthenia gravis patients[J].Autoimmunity,2012,45(2):153-160.
[20] Romi F,Suzuki S,Suzuki N,et al.Anti-voltage-gated Potassium Channel Kv1.4 antibodies in myasthenia gravis[J].J Neurol,2012,259(7):1312-1316.
[21] Ikeguchi R,Shimizu Y,Suzuki S,et al.Japanese cases of neuromyelitis optica spectrum disorder associated with myasthenia gravis and a review of the literature[J].Clin Neurol Neurosurg,2014,125(8):217-221.
[22] Balarabe SA,Adamu MD,Watila MM,et al.Neuromyelitis optica and myasthenia gravis in a young Nigerian girl[Z],2015.
[23] Zhang M,Li H,Guo J,et al.Different molecular expression in thymoma with ocular or generalized myasthenia gravis[J].J Neurol Sci,2012,313(1/2):27-31.
[24] Masuda M,Matsumoto M,Tanaka S,et al.Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients[J].J Neuroimmunol,2010,225(1/2):123-131.
[25] Nessi V,Nava S,Ruocco C,et al.Naturally occurring CD4+CD25+ regulatory T cells prevent but do not improve experimental myasthenia gravis[J].J Immunol,2010,185(9):5656-5667.
[26] Alahgholi-Hajibehzad M,Oflazer P,Aysal F,et al.Regulatory function of CD4(+)CD25(++)T cells in patients with myasthenia gravis is associated with phenotypic changes and STAT5 signaling: 1,25-Dihydroxyvitamin D3 modulates the suppressor activity[J].J Neuroimmunol,2015,281:51-60.
[27] Hamdoon MN,Fattouh M,El-Din AN,et al.The potential role of cell surface complement regulators and circulating CD4+ CD25+ T-cells in the development of autoimmune myasthenia gravis[J].Electronic physician,2016,8(1):1718-1726.
[28] Aricha R,Mizrachi K,Fuchs S,et al.Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis[J].J Autoimmun,2011,36(2):135-141.
[29] Anderson D,Phan C,Johnston WS,et al.Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up[J].Annals of clinical and translational neurology,2016,3(7):552-555.
[30] Howard JF,Barohn RJ,Cutter GR,et al.A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis[J].Muscle Nerve,2013,48(1):76-84.